Thermo Fisher Scientific Human Noggin Recombinant Protein, PeproTech

Applications

Tested Dilution

Publications

Immunohistochemistry (IHC)

-

View 1 publication 1 publication

Flow Cytometry (Flow)

-

View 1 publication 1 publication

Functional Assay (Functional)

Assay-dependent

View 1 publication 1 publication

Inhibition Assays (IA)

-

View 1 publication 1 publication

In vitro Assay (IV)

-

View 140 publications 140 publications

Miscellaneous PubMed (Misc)

-

View 33 publications 33 publications

Product Specifications

Species

Human

Published species

Bovine, Chicken, Dog, Human, Mouse, Pig, Rat

Expression System

HEK293 cells

Amino acid sequence

QHYLHIRPAP SDNLPLVDLI EHPDPIFDPK EKDLNETLLR SLLGGHYDPG FMATSPPEDR PGGGGGAAGG AEDLAELDQL LRQRPSGAMP SEIKGLEFSE GLAQGKKQRL SKKLRRKLQM WLWSQTFCPV LYAWNDLGSR FWPRYVKVGS CFSKRSCSVP EGMVCKPSKS VHLTVLRWRC QRRGGQRCGW IPIQYPIISE CKCSC

Molecular weight

46 kDa

Class

Recombinant

Type

Protein

Purity

≥ 95% by SDS-PAGE gel and HPLC analyses.

Endotoxin concentration

<1 EU/µg

Activity

Determined by its ability to inhibit 5.0 ng/ml of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrogenic cells. The expected ED50 for this effect is 2.0-3.0 ng/ml of Noggin.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

purified

Contains

no preservative

Storage conditions

-20°C

Product Specific Information

120-10C-1MG will be provided as 2 x 500 µg (120-10C-500UG).

Recombinant Human Noggin is a 46 kDa disulfide-linked homodimer consisting of two 205 amino acid polypeptide chains. Monomeric glycosylated noggin migrates at an apparent molecular weight of approximately 28.0-33.0 kDa by SDS PAGE analysis under reducing conditions.

This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Target Information

Noggin is involved in numerous developmental processes, such as neural tube fusion and joint formation. The morphogenesis of organs is initiated by a downgrowth from a layer of epithelial stem cells. This process is achieved through the receipt of signals from 1) a WNT protein (WNT3A) to stabilize beta-catenin; and 2) Noggin, which is a bone morphogenetic protein inhibitor. Noggin mutations in unrelated families with proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) have been identified, which have multiple joint fusion as their principal defect.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.